RxDoctor Payments Data

Elijah Mays, APRN

Nurse Practitioner · Columbia, SCNPI 1992317366

Payments from drug & device makers

$469in general payments, 2019–2025

Across 19 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$232
  • Lilly USA, LLC$82
  • AbbVie$63
  • Amgen$23
  • Xeris Pharmaceuticals, Inc.$21
  • Boehringer Ingelheim$21
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$469 in reported general payments places this provider in the 70th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$278
Medicare patients
11
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$27,424
FarxigaDapagliflozin Propanediol20$15,121
JanuviaSitagliptin Phosphate13$13,403
XareltoRivaroxaban15$9,258
SymbicortBudesonide/Formoterol Fumarate11$3,446
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,509
Albuterol Sulfate HfaAlbuterol Sulfate44$1,019
Ventolin HfaAlbuterol Sulfate14$736
Atorvastatin Calcium64$488
Gabapentin31$448
Omeprazole27$438
Amlodipine Besylate75$425
Metformin Hcl50$391
Rosuvastatin Calcium39$350
Prednisone33$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$232$18,56731 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$16119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →